In a 54-year-old female with a right cheek abscess and a history of hidradenitis suppurativa (first facial lesion), what additional therapy besides doxycycline, such as ceftriaxone, should be considered to reduce swelling and pain?

Immediate Management Recommendation

Start doxycycline as planned, but do NOT add ceftriaxone—instead, consider intralesional triamcinolone (10 mg/mL) for immediate pain and swelling relief, and ensure urgent dermatology referral within days given this is her first facial HS lesion. 1

Rationale for This Approach

Why Doxycycline Alone is Appropriate

Doxycycline is a reasonable systemic antibiotic choice for HS, though the evidence is limited. The North American HS guidelines note that doxycycline 100 mg twice daily has been studied primarily in combination with adalimumab, without independent evidence of superior outcomes 1. However, tetracyclines remain guideline-supported for mild-to-moderate disease 1, 2. Recent data on 40 mg modified-release doxycycline showed HiSCR50 response in 75.8% of patients at 12 weeks 3, suggesting efficacy for acute flares.

Why NOT Ceftriaxone

Ceftriaxone has no established role in HS management. The FDA labeling for ceftriaxone indicates use for bacterial infections (gonococcal, surgical prophylaxis, etc.) 4, but HS is fundamentally an inflammatory follicular disorder, not a primary bacterial infection 5, 6. The guidelines make no mention of ceftriaxone for HS 1. Adding an IV cephalosporin would be:

• Inappropriate escalation without evidence
• Potentially harmful (adverse events include hypersensitivity, GI effects, hematologic changes) 4
• Contributes to antimicrobial resistance without therapeutic benefit 6

What WILL Help Swelling and Pain Immediately

Intralesional triamcinolone acetonide (10 mg/mL, 0.2-2.0 mL) directly into the inflamed lesion provides rapid symptom relief. A prospective case series demonstrated significant reductions in erythema, edema, suppuration, and size, with significant pain reduction within 1 day 1. This is your best option for immediate symptom control while awaiting dermatology.

Specific Management Algorithm

Immediate Actions (Today):

1. Start doxycycline 100 mg twice daily (or 40 mg modified-release if available and preferred for safety profile) 3
2. Consider intralesional triamcinolone 10 mg/mL (0.2-2.0 mL into the abscess) for rapid pain/swelling reduction 1
3. Add topical clindamycin 1% solution to the facial lesion—this has RCT evidence for reducing pustules and improving patient self-assessment 1, 7
4. Recommend antiseptic cleansers (chlorhexidine or benzoyl peroxide) for the affected area 1

Urgent Referral (Within Days):

• Dermatology consultation is critical because:
  • This is her first facial presentation—atypical location requiring specialist evaluation 8
  • Facial HS can be diagnostically challenging and may require biopsy to exclude other conditions 8
  • She may need escalation to combination antibiotics (clindamycin 300 mg + rifampin 300 mg twice daily is the best-studied regimen for moderate-severe HS) 1, 2
  • If inadequate response, biologics (adalimumab) or surgical options should be considered 9, 2

Follow-up Monitoring:

• Assess response at 1-2 weeks: Look for reduction in pain, swelling, and abscess size
• If worsening or no improvement: Escalate to clindamycin + rifampin combination (300 mg each, twice daily) 1
• Watch for relapse: 33% relapse rate at 6 months with doxycycline alone 3

Critical Pitfalls to Avoid

1. Don't treat this as simple cellulitis or bacterial abscess—HS is inflammatory, not infectious, despite its appearance 5, 6
2. Don't delay dermatology referral—facial involvement is rare and requires specialist input 8
3. Don't use ceftriaxone or other non-evidence-based antibiotics—this contributes to resistance without benefit 6
4. Don't forget comorbidity screening—HS patients have increased risk of obesity, metabolic syndrome, diabetes, and increased all-cause mortality (incidence rate ratio 1.35) 9

Special Considerations for Facial HS

Facial HS is exceptionally rare and presents unique challenges 8. One recent case report described periorbital involvement complicated by cellulitis in a patient with uncontrolled diabetes 8. Ensure her diabetes (if present) or other metabolic conditions are optimized, as these affect outcomes 3.